John C. Stendahl

Cardiology

5 Columbus Cir
New York, NY 10019

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 42 publications

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Journal: Circulation

Published: June 22, 2026

The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Journal: Circulation

Published: April 17, 2026

Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.

Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy.

Journal: Circulation

Published: March 09, 2026

Blunted heart rate response to regadenoson predicts cardiovascular risk beyond quantitative positron emission tomography myocardial blood flow.

Blunted heart rate response to regadenoson predicts cardiovascular risk beyond quantitative positron emission tomography myocardial blood flow.

Journal: Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

Published: February 16, 2026

Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy.

Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy.

Journal: JAMA cardiology

Published: January 07, 2026

Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry.

Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry.

Journal: Journal of the American College of Cardiology

Published: December 09, 2025

Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy.

Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA-Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy.

Journal: Circulation

Published: September 22, 2025

Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation.

Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation.

Journal: Journal of the American Heart Association

Published: August 23, 2025

Current management of hypertrophic cardiomyopathy.

Current management of hypertrophic cardiomyopathy.

Journal: BMJ (Clinical research ed.)

Published: May 27, 2025

Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.

Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.

Journal: Circulation

Published: March 17, 2025

Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy.

Sex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy.

Journal: Circulation. Genomic and precision medicine

Published: January 24, 2025

Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.

Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy.

Journal: Circulation

Published: December 05, 2024

Showing 1-12 of 42

Last Updated: 09/26/2026